Trials / Completed
CompletedNCT01435525
Nexium Capsules Helicobacter Pylori Specific Clinical Experience Investigation
Nexium Capsules Specific Clinical Experience Investigation Concerning Helicobacter Pylori Eradication
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 369 (actual)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to confirm the safety profile / factors which impact safety and efficacy in patients given triple therapy for Helicobacter pylori eradication with Nexium + amoxicillin (AMPC) + clarithromycin (CAM), or Nexium + AMPC + metronidazole (MNZ) in usual post-marketing use.
Detailed description
Nexium capsules Specific Clinical Experience Investigation concerning Helicobacter pylori eradication
Conditions
- Gastric Ulcer
- Duodenal Ulcer
- Gastric Mucosa-associated Lymphoid Tissue (MALT)
- Lymphoma Idiopathic Thrombocytopenic Purpura
- Early Gastric Cancer
Timeline
- Start date
- 2011-09-01
- Primary completion
- 2014-03-01
- Completion
- 2014-03-01
- First posted
- 2011-09-16
- Last updated
- 2014-04-16
Locations
36 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT01435525. Inclusion in this directory is not an endorsement.